1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Progyny, Inc.
  6. News
  7. Summary
    PGNY   US74340E1038

PROGYNY, INC.

(PGNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Berenberg Bank Adjusts Progyny's Price Target to $71 From $80, Maintains Buy Rating

01/19/2022 | 09:23am EDT


© MT Newswires 2022
All news about PROGYNY, INC.
05/18PGNY STOCK NEWS : Robbins LLP Investigates Progyny, Inc. (PGNY) on Behalf of Shareholders
BU
05/11TRANSCRIPT : Progyny, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
CI
05/06PROGYNY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/06The Broken Brown Egg and Progyny Launch the Awareness, Hope, and Activism Grant™ ..
GL
05/06Berenberg Bank Adjusts Progyny's Price Target to $66 From $70, Maintains Buy Rating
MT
05/05PROGYNY : Q1 Earnings Snapshot
AQ
05/05CORRECTION : Guidance: (pgny) progyny q1 eps $0.05
MT
05/05GUIDANCE : (PGNY) PROGYNY Sees Q2 EPS $0.05
MT
05/05Earnings Flash (PGNY) PROGYNY Posts Q1 Revenue $172.2M, vs. Street Est of $167.2M
MT
05/05TRANSCRIPT : Progyny, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
More news
Analyst Recommendations on PROGYNY, INC.
More recommendations
Financials (USD)
Sales 2022 757 M - -
Net income 2022 10,3 M - -
Net cash 2022 196 M - -
P/E ratio 2022 183x
Yield 2022 -
Capitalization 3 235 M 3 235 M -
EV / Sales 2022 4,01x
EV / Sales 2023 2,80x
Nbr of Employees 312
Free-Float 83,9%
Chart PROGYNY, INC.
Duration : Period :
Progyny, Inc. Technical Analysis Chart | PGNY | US74340E1038 | MarketScreener
Technical analysis trends PROGYNY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 35,18 $
Average target price 62,83 $
Spread / Average Target 78,6%
EPS Revisions
Managers and Directors
Peter Anevski Chief Executive Officer & Director
Michael Sturmer President
Mark Livingston Chief Financial Officer
David J. Schlanger Executive Chairman
Alan B. Copperman Medical Director
Sector and Competitors
1st jan.Capi. (M$)
PROGYNY, INC.-30.13%3 235
UNITEDHEALTH GROUP-3.27%455 698
ANTHEM, INC.6.32%118 819
CIGNA CORPORATION13.00%82 329
HUMANA INC.-5.23%55 609
CENTENE CORPORATION3.11%49 692